Proactive Investors
02 Oct 2026, 06:44 UTC · 3d ago
Eli Lilly obesity drug data adds pressure on Novo Nordisk
Impact · against what's priced in
The news is a moderate positive for Eli Lilly as it provides clinical evidence for the 'unpriced' next-generation pipeline, though high discontinuation rates temper the immediate impact. For Novo Nordisk, the data creates a competitive headwind for CagriSema, but the exact impact is unclear without a baseline priced-in reconstruction.
- LLY+0.30
Challenges what's priced in
- The price assumes
The next-generation pipeline, specifically retatrutide's potential for superior weight loss, which is unpriced
The price currently declines to pay for next-gen pipeline success; EloraTZP's 23.3% weight loss provides concrete evidence for this unpriced potential, though the 10.8%-27% discontinuation rate suggests a tolerability hurdle.
What LLY's price assumes · Sep 10
Top 1 mover · tap to explore
